182 related articles for article (PubMed ID: 29797711)
1. Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?
Berntsson SG; Kristoffersson A; Boström I; Feresiadou A; Burman J; Landtblom AM
Acta Neurol Scand; 2018 Oct; 138(4):327-331. PubMed ID: 29797711
[TBL] [Abstract][Full Text] [Related]
2. Rituximab in multiple sclerosis at general hospital level.
Hellgren J; Risedal A; Källén K
Acta Neurol Scand; 2020 Jun; 141(6):491-499. PubMed ID: 31990978
[TBL] [Abstract][Full Text] [Related]
3. Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
Alping P; Neovius M; Piehl F; Frisell T
Ann Neurol; 2024 Jun; 95(6):1099-1111. PubMed ID: 38529711
[TBL] [Abstract][Full Text] [Related]
4. Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Rommer PS; Dörner T; Freivogel K; Haas J; Kieseier BC; Kümpfel T; Paul F; Proft F; Schulze-Koops H; Schmidt E; Wiendl H; Ziemann U; Zettl UK;
J Neuroimmune Pharmacol; 2016 Mar; 11(1):1-8. PubMed ID: 26589235
[TBL] [Abstract][Full Text] [Related]
5. Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Neurology; 2016 Nov; 87(20):2074-2081. PubMed ID: 27760868
[TBL] [Abstract][Full Text] [Related]
6. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations.
Eriksson I; Komen J; Piehl F; Malmström RE; Wettermark B; von Euler M
Eur J Clin Pharmacol; 2018 May; 74(5):663-670. PubMed ID: 29429031
[TBL] [Abstract][Full Text] [Related]
7. A retrospective observational study of rituximab treatment in multiple sclerosis patients in Cyprus.
Leonidou E; Pantzaris M; Kleopa KA; Loizidou MA; Kyriakides T; Christou YP
Postgrad Med; 2019 Sep; 131(7):486-489. PubMed ID: 31353999
[No Abstract] [Full Text] [Related]
8. Rituximab for the treatment of multiple sclerosis: a review.
Chisari CG; Sgarlata E; Arena S; Toscano S; Luca M; Patti F
J Neurol; 2022 Jan; 269(1):159-183. PubMed ID: 33416999
[TBL] [Abstract][Full Text] [Related]
9. Rituximab in paediatric onset multiple sclerosis: a case series.
Salzer J; Lycke J; Wickström R; Naver H; Piehl F; Svenningsson A
J Neurol; 2016 Feb; 263(2):322-326. PubMed ID: 26603152
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
Yamout BI; El-Ayoubi NK; Nicolas J; El Kouzi Y; Khoury SJ; Zeineddine MM
J Immunol Res; 2018; 2018():9084759. PubMed ID: 30539030
[TBL] [Abstract][Full Text] [Related]
11. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies.
Dunn N; Juto A; Ryner M; Manouchehrinia A; Piccoli L; Fink K; Piehl F; Fogdell-Hahn A
Mult Scler; 2018 Aug; 24(9):1224-1233. PubMed ID: 28762877
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in the treatment of multiple sclerosis in the Hospital District of Southwest Finland.
Airas L; Nylund M; Mannonen I; Matilainen M; Sucksdorff M; Rissanen E
Mult Scler Relat Disord; 2020 May; 40():101980. PubMed ID: 32066031
[TBL] [Abstract][Full Text] [Related]
14. [Rituximab: its efficacy, effectiveness and safety in the treatment of multiple sclerosis].
Midaglia L; Mora L; Mulero P; Sastre-Garriga J; Montalban X
Rev Neurol; 2018 Jan; 66(1):25-32. PubMed ID: 29251340
[TBL] [Abstract][Full Text] [Related]
15. Rituximab treatment for multiple sclerosis.
Ineichen BV; Moridi T; Granberg T; Piehl F
Mult Scler; 2020 Feb; 26(2):137-152. PubMed ID: 31237800
[TBL] [Abstract][Full Text] [Related]
16. Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.
Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Ann Neurol; 2020 May; 87(5):688-699. PubMed ID: 32056253
[TBL] [Abstract][Full Text] [Related]
17. Rescue Therapy Using Rituximab for Multiple Sclerosis.
Berenguer-Ruiz L; Sempere AP; Gimenez-Martinez J; Gabaldon-Torres L; Tahoces L; Sanchez-Perez R; Diaz-Marin C
Clin Neuropharmacol; 2016; 39(4):178-81. PubMed ID: 27046661
[TBL] [Abstract][Full Text] [Related]
18. Severe neutropenia after rituximab-treatment of multiple sclerosis.
Rissanen E; Remes K; Airas L
Mult Scler Relat Disord; 2018 Feb; 20():3-5. PubMed ID: 29253744
[TBL] [Abstract][Full Text] [Related]
19. Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry.
Spelman T; Forsberg L; McKay K; Glaser A; Hillert J
Mult Scler; 2022 Jun; 28(7):1051-1059. PubMed ID: 34212816
[TBL] [Abstract][Full Text] [Related]
20. Rituximab for treating multiple sclerosis: Off-label but on target.
Bourdette D
Neurology; 2016 Nov; 87(20):2070-2071. PubMed ID: 27760871
[No Abstract] [Full Text] [Related]
[Next] [New Search]
